BID and breast carcinoma: The PKCepsilon functions result in improvement in Bcl-2 expression, and also reduction in Bid expression without any effect on Bax, and thus implying that it arbitrates TRAIL resistance through both Bcl-2 and Bid in breast cancer cells (47).